April 17, 2020 07:32 AM EDTUpdated April 20, 09:41 AM
R&D
Coronavirus

Re­port on one PhI­II remde­sivir study sends in­vestors in­to over­drive, adding bil­lions to Gilead­'s mar­ket cap

Amber Tong

Be­fore any drug is of­fi­cial­ly proven ef­fec­tive against Covid-19, every da­ta nugget sur­round­ing an ex­per­i­men­tal treat­ment un­der­stand­ably arous­es in­vestors’ and pa­tients’ hopes alike. Thurs­day night …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times